Bacci Marcelo Rodrigues, Cavallari Marina Romera, de Rozier-Alves Ross Martin, Alves Beatriz da Costa Aguiar, Fonseca Fernando Luiz Affonso
General Practice Department, Federal University of São Paulo, São Paulo, Brazil.
Clinical Analysis Laboratory, ABC Medical School, Federal University of São Paulo, São Paulo, Brazil.
Drug Des Devel Ther. 2015 Jun 22;9:3179-82. doi: 10.2147/DDDT.S82100. eCollection 2015.
Hypertension and diabetes are clinical conditions which contribute to the development of chronic kidney disease as well as risk factors for cardiovascular events. In recent years, lipocalin-type-prostaglandin-D-synthase (beta trace protein; BTP) has increasingly been studied as an alternative to creatinine for the evaluation of renal function as well as for being a possible biomarker for cardiovascular disease. It is expected that the levels of BTP in patients with cardiovascular disease are elevated, as is the case with patients with renal dysfunction. The objective of this study is to realize a systematic review of the pertinent literature in respect to BTP as a biomarker of renal dysfunction in diabetic patients. Using the database MEDLINE, a search up to year 2014 was conducted using the follow descriptors: "lipocalin type prostaglandin d synthase" AND "diabetes"; "lipocalin type prostaglandin d synthase" and "diabetic nephropathy"; "beta trace protein" AND "diabetes"; "beta trace protein" AND "diabetic nephropathy". The criteria used for inclusion were the presence of the referring to terms in title or abstract and study conducted in humans. About 17 articles were selected, of which six articles were duplicates, and of which six articles did not investigate any possible relationship between the protein (BTP) and either diabetes or nephropathy. The final result yielded five articles to be analyzed. This review found BTP is not influenced by race, by body mass index nor by patient's sex. BTP can be considered as a reliable early biomarker of renal dysfunction in diabetics. BTP is associated with metabolic syndrome and is also associated with greater cardiovascular risk. Prospective data establishing a correlation between BTP and mortality would have been of great interest, but such articles were not found in this review.
高血压和糖尿病是导致慢性肾病发展的临床病症,也是心血管事件的风险因素。近年来,脂质运载蛋白型前列腺素-D-合酶(β-微量蛋白;BTP)作为评估肾功能的替代指标以及心血管疾病的潜在生物标志物,受到了越来越多的研究。预计心血管疾病患者的BTP水平会升高,肾功能不全患者也是如此。本研究的目的是对有关BTP作为糖尿病患者肾功能不全生物标志物的相关文献进行系统综述。利用MEDLINE数据库,使用以下描述词对截至2014年的文献进行了检索:“脂质运载蛋白型前列腺素d合酶”和“糖尿病”;“脂质运载蛋白型前列腺素d合酶”和“糖尿病肾病”;“β-微量蛋白”和“糖尿病”;“β-微量蛋白”和“糖尿病肾病”。纳入标准是标题或摘要中出现相关术语且研究对象为人类。共筛选出约17篇文章,其中6篇为重复文章,6篇未研究该蛋白(BTP)与糖尿病或肾病之间的任何可能关系。最终得到5篇文章进行分析。本综述发现BTP不受种族、体重指数和患者性别的影响。BTP可被视为糖尿病患者肾功能不全的可靠早期生物标志物。BTP与代谢综合征相关,也与更高的心血管风险相关。能确定BTP与死亡率之间相关性的前瞻性数据会很有意义,但在本综述中未找到此类文章。